Literature DB >> 19786136

Optimized subunit vaccine protects against experimental leishmaniasis.

Sylvie Bertholet1, Yasuyuki Goto, Lauren Carter, Ajay Bhatia, Randall F Howard, Darrick Carter, Rhea N Coler, Thomas S Vedvick, Steven G Reed.   

Abstract

Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786136      PMCID： PMC2783536          DOI： 10.1016/j.vaccine.2009.09.066

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  57 in total

1.  Role of T cell subsets during the recall of immunologic memory to Leishmania major.

Authors:  I Müller
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

2.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.

Authors:  L F Fries; D M Gordon; R L Richards; J E Egan; M R Hollingdale; M Gross; C Silverman; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis.

Authors:  R G Titus; G Milon; G Marchal; P Vassalli; J C Cerottini; J A Louis
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

4.  Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major.

Authors:  I Müller; P Kropf; J A Louis; G Milon
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

Review 5.  Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.

Authors:  Lawrence R Stanberry
Journal:  Herpes       Date:  2004-08

Review 6.  Leishmaniasis: current status of vaccine development.

Authors:  Bindu Sukumaran; Rentala Madhubala
Journal:  Curr Mol Med       Date:  2004-09       Impact factor: 2.222

7.  Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells.

Authors:  I Müller; P Kropf; R J Etges; J A Louis
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 8.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.

Authors:  Jory R Baldridge; Patrick McGowan; Jay T Evans; Christopher Cluff; Sally Mossman; David Johnson; David Persing
Journal:  Expert Opin Biol Ther       Date:  2004-07       Impact factor: 4.388

Review 9.  The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.

Authors:  Phillip Scott; David Artis; Jude Uzonna; Colby Zaph
Journal:  Immunol Rev       Date:  2004-10       Impact factor: 12.988

10.  A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

Authors:  Y A Skeiky; J A Guderian; D R Benson; O Bacelar; E M Carvalho; M Kubin; R Badaro; G Trinchieri; S G Reed
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307
View more
  46 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

3.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

Review 4.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

5.  Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.

Authors:  S S Kashino; C Abeijon; L Qin; K A Kanunfre; F S Kubrusly; F O Silva; D L Costa; D Campos; C H N Costa; I Raw; A Campos-Neto
Journal:  Parasite Immunol       Date:  2012-07       Impact factor: 2.280

6.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

7.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

8.  Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.

Authors:  Dirlei Nico; Carla Claser; Gulnara P Borja-Cabrera; Luiz R Travassos; Marcos Palatnik; Irene da Silva Soares; Mauricio Martins Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2010-11-09

9.  Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

Authors:  Nathan C Peters; Sylvie Bertholet; Phillip G Lawyer; Melanie Charmoy; Audrey Romano; Flavia L Ribeiro-Gomes; Lisa W Stamper; David L Sacks
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

10.  Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery.

Authors:  Grace Ledet; Sarala Pamujula; Valencia Walker; Shana Simon; Richard Graves; Tarun K Mandal
Journal:  Drug Dev Ind Pharm       Date:  2013-04-19       Impact factor: 3.225
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.